GlassScriptPhysician profile
Keionna Grant
NPI 1427581461
$6,771.26
in general payments reported to CMS, 2019-2025
15 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,625 · 2023: $14.18 · 2024: $537 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,828.77 | 2022-2025 | Amplatzer Amulet |
| Heartflow, INC. | $256.24 | 2023-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $162.49 | 2024-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $132.26 | 2024 | Pascal |
| Amgen INC. | $71.94 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $69.70 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $47.47 | 2024-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $41.26 | 2025 | Verquvo |
| Abiomed | $26.38 | 2025 | |
| Novo Nordisk INC | $25.40 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $23.77 | 2025 | Nexletol |
| Bridgebio Pharma, INC. | $23.54 | 2025 | Attruby |
| Cvrx, INC. | $22.99 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $20.91 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.14 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keionna Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.